IPO - Can-Fite BioPharma Ltd.

Form Type: 424B5

Filing Date: 2025-04-15

Corporate Action: Ipo

Type: New

Accession Number: 000121390025031857

Filing Summary: Can-Fite BioPharma Ltd. is offering 750,000,000 ordinary shares represented by 2,500,000 American Depositary Shares (ADSs) at an offering price of $1.20 per ADS. Each ADS represents 300 ordinary shares. The closing price of the ADSs on April 11, 2025, was $1.57. This offering is pursuant to a shelf registration statement filed with the SEC, and the expected delivery date of the securities is on or about April 15, 2025. The company retains H.C. Wainwright & Co., LLC as its exclusive placement agent, taking 7% of gross proceeds as a fee. The net proceeds from this offering are expected to be about $2.64 million, earmarked for research, development, and general corporate purposes. The document highlights significant risks associated with investing in the securities, warns against reliance on forward-looking statements, and indicates the company has incurred significant losses and requires capital for operational sustainability. The ADSs are listed on the NYSE American under the symbol CANF and also trade on the Tel Aviv Stock Exchange.

Form Type: POS AM

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025031575

Filing Summary: On April 14, 2025, Can-Fite BioPharma Ltd. filed Post-Effective Amendment No. 8 to its Form F-1 registration statement. This filing includes an updated prospectus for the resale of a total of approximately 61,889,400 ordinary shares by selling shareholders represented by 206,298 American Depositary Shares (ADSs). The registration statement consolidates updates from three previous filings: a February 2023 Registration Statement covering 28,636,500 ordinary shares from the Registered Direct Offering (RD Offering) and PIPE Offering; an August 2021 Registration Statement for 10,500,000 ordinary shares from a private placement; and a March 2020 Registration Statement relating to 22,752,900 ordinary shares from the January 2020 Private Placement. The prospectus highlights the various offerings and SEC registration requirements but clarifies that no new securities are being registered. The selling shareholders will receive all proceeds from the resale, while Can-Fite may benefit from any warrant exercises. The filing underlines the high-risk potential associated with the offered securities, acknowledging various factors that could impact future investment outcomes.